Head-to-head comparison of Tirzepatide and Semaglutide — the two most-studied GLP-1 class peptides for fat loss. Compare mechanisms, clinical trial data, dosing, and looksmaxxing applications.
Dual GIP/GLP-1 receptor agonist studied for weight management and metabolic health.
GLP-1 receptor mono-agonist — mimics endogenous GLP-1 to slow gastric emptying, suppress appetite via hypothalamic signaling, and improve insulin sensitivity through pancreatic beta cell activity.
Side-by-Side Comparison
| Property | Tirzepatide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| Mechanism | Dual GIP/GLP-1 receptor agonist — activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously, producing greater fat loss than GLP-1 mono-agonism alone. | GLP-1 receptor mono-agonist — mimics endogenous GLP-1 to slow gastric emptying, suppress appetite via hypothalamic signaling, and improve insulin sensitivity through pancreatic beta cell activity. |
| Half-Life | ~5 days | ~7 days |
| Typical Dosage | 2.5 mg/week SC, titrate to 5–15 mg/week | 0.25 mg/week SC, titrate to 1–2.4 mg/week |
| Primary Use | Fat loss, appetite suppression, visceral adiposity reduction, body composition optimization | Fat loss, blood glucose regulation, appetite suppression, cardiovascular risk reduction |
| Onset | 4–8 weeks for measurable weight loss; peak body composition at 20–72 weeks | 4–12 weeks for measurable weight loss; peak effects at 68 weeks |
| Stacks Well With | CJC-1295, Ipamorelin, MOTS-C, AOD-9604 | MOTS-C, 5-Amino-1MQ, CJC-1295 |
Overview
Dual GIP/GLP-1 receptor agonist — activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously, producing greater fat loss than GLP-1 mono-agonism alone.
GLP-1 receptor mono-agonist — mimics endogenous GLP-1 to slow gastric emptying, suppress appetite via hypothalamic signaling, and improve insulin sensitivity through pancreatic beta cell activity.
Applications & Benefits
- Dual GIP + GLP-1 mechanism — superior fat loss vs GLP-1 alone
- SURMOUNT-5 trial: 18% avg weight loss vs 14.4% for semaglutide
- Stronger visceral and subcutaneous fat reduction data
- Weekly injection frequency
- Better tolerated GI side effect profile in head-to-head data
- Longest clinical history in GLP-1 class
- STEP trial: up to 14.9% body weight loss
- FDA-approved (Ozempic, Wegovy) — extensive human safety data
- Weekly dosing at lower absolute dose
- Strong cardiovascular outcome data (SELECT trial)
Tirzepatide vs Semaglutide: Bottom Line
In the first head-to-head clinical trial (SURMOUNT-5, NEJM 2025), tirzepatide produced 18% average body weight reduction versus 14.4% for semaglutide — a statistically significant difference at 72 weeks. For maximum fat loss and body composition improvement, tirzepatide's dual mechanism gives it a measurable edge. For cardiovascular outcomes and the longest clinical track record, semaglutide remains highly validated. For looksmaxxing goals centered on adiposity reduction, tirzepatide is the current evidence-based first choice.
Compare Other Peptides
Mix and match any of the 19 peptides in our catalog for a custom side-by-side comparison.
Build New Comparison